WO1999015197A1 - Präparat zur behandlung von blutgerinnungsstörungen - Google Patents
Präparat zur behandlung von blutgerinnungsstörungen Download PDFInfo
- Publication number
- WO1999015197A1 WO1999015197A1 PCT/AT1998/000228 AT9800228W WO9915197A1 WO 1999015197 A1 WO1999015197 A1 WO 1999015197A1 AT 9800228 W AT9800228 W AT 9800228W WO 9915197 A1 WO9915197 A1 WO 9915197A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- factor
- prothrombin
- preparation
- preparation according
- derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6429—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21005—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the present invention relates to a pharmaceutical preparation, in particular for the treatment of blood coagulation disorders, containing coagulation factors which are part of a prothrombinase or pro-prothrombinase.
- Prothrombinase is an enzyme-substrate complex that forms on a phospholipid surface and enables the activation of prothrombin.
- prothrombinase consists of factor II (prothrombin), activated factor X (factor Xa), cofactor V or Va, phospholipids and calcium ions. These factors exist in vivo as a transient complex for activating the prothrombin and formation of the thrombin.
- a corresponding pro-prothrombinase is defined as a complex of factors which are at least partially modified or activated to form a prothrombinase.
- the pro-prothrombinase is therefore to be understood as a precursor of the prothrombinase and as a complex in which one or more components are present in their precursors, as zymogens or as proforms and which is formed on the basis of affinities of the components to one another.
- Hemophilia A arises from an X-linked recessive hereditary deficiency of factor VIII and manifests itself in severe blood clotting disorders. Coagulation-active plasma protein concentrates are mostly used to stop acute bleeding, mainly factor VIII concentrates. In the classic treatment of haemophilia A patients with factor VIII preparations, however, antibodies to factor VIII are formed in around 20% of the cases, which lead to an inhibition of the effect of the administered factor VIII preparations. It is then said that a patient has formed a functional factor VIII inhibitor and has developed a factor VIII inhibitor hemophilia or acquired hemophilia.
- the antibody directed against factor VIII is thus neutralized in vivo and the excess factor VIII can develop its haematostatic cofactor activity.
- Repeated administration over a longer period of time desensitizes the patient to factor VIII and can then be subjected to the usual factor VIII concentrate therapy in many cases. This procedure requires extremely large amounts of factor VIII, is time-consuming and can be associated with massive anaphylactic side effects at the beginning of the treatment.
- Another complex method for removing the factor VIII inhibitors is the extracorporeal immune absorption to either lectins which bind immunoglobulins (protein A, protein G) or immobilized factor VIII, to which the antibody formed against factor VIII is bound.
- This method is complex for the patient because he is bound to an apheresis machine, like the previous ones, can not stop acute bleeding and is also expensive.
- the therapy of choice is currently the administration of activated prothrombin complex concentrates (APCC), FEIBA ® , AUTOPLEX ® , which are used in patients with high inhibitor titers to stop acute bleeding disorders. gene can be used (see for example DE-PS 31 27 318 (2)).
- activated factor VIII a component that was included in these is also included, namely activated factor VIII, proposed as a therapeutic principle for factor VIII inhibitor patients via the route of extrinsic coagulation.
- a corresponding preparation, namely recombinant factor VIIa is currently in clinical trials (Hedner et al., Transfusion Medicine Reviews 7 (2): 78-83 (1993)).
- Preclinical examinations, e.g. on dogs with haemophilia A have shown that treatment with recombinant factor VIIa is ineffective.
- the success rate in human use is only fluctuating.
- Another disadvantage of the recombinant factor VIIa is that due to its short in vivo half-life it often has to be given in high doses per day in order to be able to control, if at all, heavy bleeding. In such cases, an attempt is made to co-administer factor VIII with antifibrinolytics to support the effect.
- the present invention therefore has as its object to avoid the disadvantages of the described methods and to provide a therapeutic principle for the treatment of blood coagulation disorders, in particular for the treatment of factor VIII inhibitor hemophilia, which among other things is simple to use and has an effective effect, an extended half-life and avoidance of thrombogenic side effects kungen enables.
- a pharmaceutical preparation for the treatment of blood coagulation disorders containing at least two coagulation factors which are components of a prothrombinase or pro-prothrombinase as active components, in particular with a preparation containing purified prothrombin and purified factor Xa as active components, preferably one of the factors other than prothrombin is activated.
- the components are preferably cleaned at least to such an extent that they are free from endogenous, i.e. phospholipids originating from the starting material, but also, in particular, phospholipid vesicles.
- this prevents premature thrombin formation and ensures the stability of the pharmaceutical preparation, and on the other hand minimizes the risk of thromboembolic side effects.
- a mixture or complex of at least two constituents of the prothrombinase is understood according to the invention as a "partial prothrombinase”.
- prothrombinase or pro-prothrombinase In addition to the components of prothrombinase or pro-prothrombinase, other factors of blood coagulation and fibrinolysis are advantageously included in order to achieve an attenuated effect, in particular an intensification, weakening, acceleration or deceleration of the hemostasis. Accordingly, activators or proactivators of blood coagulation, including factors of intrinsic or extrinsic blood coagulation, as zymogens or as activated factors, and their agonists or antagonists or inhibitors can also be included. In addition, the corresponding combinations are possible as preparations that are used separately. This includes the combination with fibrinogen, which is particularly suitable for local application.
- the pharmaceutical preparation essentially consists of the "partial len prothrombinase ", the components of the prothrombinase or pro-prothrombinase preferably being bound as a complex.
- This complex can be purified and treated in a simple manner, in particular for the inactivation of molecular, microbial or viral pathogens, and can be treated chemically and / or physically.
- the factors of the pharmaceutical preparation according to the invention are contained in a form which enables the activation of at least one factor or in which at least one factor is already activated. Human factors are preferably added as factors.
- the factors in the pharmaceutical preparation according to the invention are preferably selected from the group consisting of factors II, V, Va, X and Xa.
- Combinations of factors II and V or Va as well as X and V or Va are preferably provided as the preparation of a partial prothrombinase or pro-prothrombinase according to the invention. It is particularly preferred that the preparation according to the invention essentially consists of these combinations. Similarly, a pro-prothrombinase consisting of factors II and X, optionally in combination with factor V or Va, is a preferred embodiment of the present invention.
- Native factors such as proteins or their equivalents obtained from plasma or a plasma fraction, which are encoded, for example, by recombinant nucleic acids, can be used.
- corresponding derivatives which comprise the modified proteins or fragments are also suitable, as long as they can be activated or have the corresponding activity in order to modulate the generation of thrombin.
- a preparation for the treatment of blood coagulation disorders based on prothrombin or a prothrombin derivative comprising a peptide sequence modified in an area essential for the activation to thrombin, which sequence is of a type for the activation of prothrombin coagulation-physiologically foreign protease, that is, a non-coagulation-physiological protease is recognized.
- non-coagulation-physiological protease or “coagulation-physiologically foreign protease” is understood to mean a protease which does not directly activate the prothrombin to thrombin in the human coagulation system. Proteases that indirectly activate native prothrombin are therefore to be understood as coagulation-physiological proteases according to the present definition. Only human activated factor X is a protease that exerts this direct activating effect in the human coagulation system. The modified peptide sequence of human activated factor X is therefore preferably not recognized.
- proteases which are naturally active in the coagulation system and fibrinolysis system, in particular in the human coagulation system, are preferred, but proteases derived, for example, from toxins or from snake venoms are also suitable according to the invention.
- Preferred proteases are those selected from the group consisting of endoprotease, serine protease, metalloprotease, cysteine protease, aspartic acid protease, calcium-dependent protease and vWF-dependent protease. Derivatives of these can also be used.
- proteases used in the present invention are elastase, e.g. Called leukocyte elastase, kallikrein, plasmin, thrombin, factor Xlla, factor XIa or activated protein C.
- elastase e.g. Called leukocyte elastase, kallikrein, plasmin, thrombin, factor Xlla, factor XIa or activated protein C.
- the peptide sequence contained in the prothrombin or prothrombin derivative generally depends on the protease to be used or used. Proteases and corresponding cleavage sequences are given as examples in the table below. Teibelle
- the preparation according to the invention is a preparation produced recombinantly, for example after expression in a mammalian cell, such as e.g. CHO, BHK or COS cells.
- the preparation may contain further substances, preferably substances selected from the group consisting of blood factor, enzyme derivative specific for the prothrombin derivative, cofactor of the enzyme derivative and inhibitor or combinations thereof.
- prothrombin in particular native prothrombin and / or factor X, is added as the blood factor.
- prothrombin forms that is to say native forms and modified forms, for example, can thus also be present in a preparation.
- Factor Xa or a catalytically active part thereof should be mentioned as an example of an enzyme derivative.
- a cofactor is preferably factor V, factor Va or a catalytically active part of factor Va, and activated protein C and / or the zymogen is preferably used as an inhibitor.
- the prothrombin or the prothrombin derivative and one of the other substances already mentioned is present as a fusion protein.
- the combination of prothrombin or a prothrombin derivative with factor Xa is particularly preferably selected for a fusion protein.
- the fusion protein can be produced according to the techniques known from the prior art, for example it is produced by means of recombinant techniques, but chemical methods, such as, for example, synthesis via a suitable linker, are also possible according to the invention.
- the fusion protein is particularly characterized by its stability. This makes it possible to use the fusion protein together with prothrombin or the prothrombin derivative according to the present invention as a preparation, in particular as a stable pharmaceutical preparation. However, the preparation can also contain the fusion protein without Contain prothrombin or prothrombin derivative.
- a preparation according to the present invention can thus have a partial prothrombinase activity or a pro-prothrombinase activity as such, or can only develop such activities after administration in vivo.
- the preparation according to the invention is free of phospholipids. This may reduce or eliminate the risk of thrombosis.
- the prothrombin or the prothrombin derivative according to the present invention and a substance selected from the group consisting of blood factor, enzyme derivative specific for the prothrombin derivative, cofactor of the enzyme derivative and inhibitor or a combination thereof can also be present as a mixture.
- the preparation according to the invention can also be formulated as a pharmaceutical preparation, for example by formulation in a buffer suitable for this purpose and optionally with the addition of stabilizers.
- a preparation according to the present invention, which contains a corresponding fusion protein, can therefore be formulated directly into a pharmaceutical preparation or split in vitro before the pharmaceutical formulation and only then formulated into a pharmaceutical preparation.
- the use of a preparation according to the invention for the production of a medicinal product results.
- a set suitable for the production of a preparation or a pharmaceutical preparation which contains as components the prothrombin or prothrombin derivative according to the invention (containing a peptide sequence modified in an area essential for activation to thrombin, which is derived from a for the prothrombin activation is recognized in the coagulation physiologically foreign protease) and comprises a corresponding protease.
- Another aspect of the present invention includes a recombined DNA coding for the prothrombin according to the invention or a prothrombin derivative, which is present in a vector suitable for expression in a mammalian cell.
- the preparation according to the invention has the advantage that, despite the high stability in vitro, it is also stable in vivo until its effectiveness is shown by the activation of prothrombin and the development of thrombin at the wound site or bleeding.
- the cellular components of the bloodstream e.g. Blood cells or vessel walls, especially surfaces containing phospholipids, generate thrombin in situ and promote hemostasis.
- factors that are purified by chromatographic processes such as ion exchange chromatography, hydrophobic chromatography, affinity chromatography and / or molecular exclusion chromatography are essentially suitable.
- specific activities of at least 50% of the theoretical purity, in particular at least 70%, preferably at least 90%, up to the theoretical purity for the individual factor can be achieved.
- a treatment for inactivating infectious pathogens for example by treatment with chemicals and / or physical treatment, such as heat treatment, radiation or filtration, in particular nanofiltration.
- the factors of the pharmaceutical preparation according to the invention are treated with detergents, which on the one hand leads to the inactivation of viruses and on the other hand existing phospholipids solubilized.
- Phospholipids can be contained in preparations of blood coagulation factors, for example from plasma or from a plasma fraction or from a cell culture.
- the special treatment of the factors for the separation of the naturally present phospholipids includes, on the one hand, the solubilization of these and, on the other hand, the separation of the phospholipids by the cleaning processes mentioned.
- the preparation can be used in combination with exogenous phospholipids, according to a further preferred variant of the preparations according to the invention, these are free of added phospholipids and contain less than 0.01 mg phospholipids / U prothrombin, which is due to the possible thrombogenic effect of phospholipids leads to a further significant reduction in the risk of thrombogenicity. According to a particularly preferred embodiment, the preparations are free of detectable phospholipid.
- the preparation according to the invention further contains magnesium ions. These ions have a competitive effect on calcium ions and can displace the calcium ions in the prothrombinase or pro-prothrombinase. This prevents premature thrombin formation in a solution of the preparation according to the invention and thus stabilizes it to such an extent that it remains stable in a solution even after hours.
- the pharmaceutical preparation can even be provided as a stable infusion solution, especially if it is ensured that it contains no free calcium ions.
- a content of a pharmaceutically acceptable chelating agent, for example EDTA, and related structures, such as citrate, are also suitable for complexing the calcium ions.
- the preparation according to the invention has a biological activity comparable to that of FEIBA® in animal models and is able to significantly reduce the clotting time of a factor VIII inhibitor plasma. It can completely normalize the prolonged bleeding time and tendency to bleed from factor VIII inhibitor rabbits and from Willebrand factor inhibitor rabbits.
- purified blood coagulation factors such as purified prothrombin and purified factor Xa
- the toxicity of the preparation according to the invention is significantly reduced compared to FEIBA ® .
- the effective combination of factor Xa and prothrombin in the Wessier thrombosis model J.Appl.Phys. 14 (1959), 943-946) has proven to be negative, ie it can be used for this combination even at higher doses than at activated prothrombin complex no thrombogenic effects can be detected in the Wessler model.
- rabbits are anesthetized with pentobarbital, then the jugular vein is dissected free under additional local anesthesia and provided with loose ligatures at a distance of 2 cm. Finally, the substance to be tested is injected into the ear vein opposite the jugular vein within 15 seconds. After a further 25 seconds, the ligatures are drawn in and waited for 10 minutes until the set vein piece can be removed and cut open in a Petri dish filled with citrate buffer and evaluated.
- the components of the pharmaceutical preparation according to the invention are preferably purified to such a purity that even at a dose of at least 150 U prothrombin / kg it is free of thromboembolic side effects, expressed by a score in the Wessler thrombosis model of at most 3, preferably is at most 2, in particular less than 2 points.
- Prothrombin is contained in the combination preparation according to the invention, preferably in a specific activity of at least 5 U / mg protein, more preferably at least 6, in particular at least 7, corresponding to 50, 60 or 70% of the theoretical purity.
- the factor X- or Xa- Preparation should preferably have a specific activity of at least 100 U / mg protein, factor Xa preferably being contained predominantly as factor Xass.
- Factor V or Va is used as a cofactor in an approximately equimolar ratio to the coagulation factor of the partial prothrombinase or pro-prothrombinase.
- the ratio is preferably (0.01-2): 1 (mol / mol), most preferably (0.5-2): 1.
- the preparation used should be as free as possible of thrombin, whereby the freedom from thrombin can be demonstrated by suitable, preferably chromogenic tests (e.g. with the chromogenic substrate TH-1 from IMMUNO AG.).
- the preparation has an increased stability compared to conventional preparations and the complex can also be subjected to a further treatment for cleaning and / or inactivating viruses.
- this further comprises antithrombin III in stabilizing amounts, optionally together with heparin, but even with such a preparation freedom from thromboembolic side effects according to the Wessler test in the absence or even after unmasking of the heparin, i.e. Neutralization and / or separation of the heparin can be demonstrated in the sense that the value of 3 points is not reached.
- the activity of a preparation based on this complex can be accelerated many times over by the presence of calcium ions, such as calcium chloride. It has also been found that a preparation containing this complex and also calcium ions can be used to prepare a reagent for diagnostic purposes.
- a reagent which also contains thrombin activity and possibly phospholipids is used, for example, for V-cofactor activity factor suitable.
- a diagnostic procedure using this reagent with or without activated protein C, a proteolytic inactivator of factor V furthermore enables the extent of inactivation of factor V or a mutation-related resistance to activated protein C to be estimated.
- a pharmaceutical preparation containing purified prothrombin as the only active component has an effect comparable to the combination preparation according to the invention in the treatment of coagulation disorders in vivo and this, although with prothrombin alone in vitro there is no reduction in the clotting time Factor VIII inhibitor plasma could be achieved.
- the present invention therefore also relates to a pharmaceutical preparation, in particular for the treatment of coagulation disorders, containing purified prothrombin as the only active component.
- the prothrombin is preferably purified to a degree that it is free of thromboembolic side effects even at a dose of at least 150 U prothrombin / kg, expressed by a score in the Wessler thrombosis mode11 of at most 3, preferably at most 2, in particular less than 2 points .
- the combination preparation according to the invention or the prothrombin preparation preferably contain less than 0.1 U factor VIII: C or factor VIII: Ag / E prothrombin or less than 0.1 U factor IX / E prothrombin or less than 0.1 U Factor X / E prothrombin.
- the prothrombin preparation can be used in combination with phospholipids, according to a further preferred variant of the preparations according to the invention, these are free of added phospholipids and contain less than 0.01 mg phospholipids / U prothrombin.
- the prothrombin preparations according to the invention are free of detectable phospholipid.
- the dosage of the preparations according to the invention is based on the dosage of the equivalent components in FEIBA ® .
- the factor eight inhibitor bypassing activity (FEIBA) is defined as the activity of such a preparation which reduces the clotting time of a factor VHI inhibitor plasma in a coagulation test as described in AT 350726 to 50% of the blank value.
- the advantages of the preparations according to the invention compared to FEIBA lie, owing to the high purity of the components, in a reduced burden on the patient with plasma proteins.
- the absence of factor VIII: Ag precludes the anaphylactic side effect.
- a dose can be administered which, for example, comprises at least 50 U prothrombin / kg body weight, this dose being administered for the first time in this type of preparation even in a bolus injection due to the absence of side effects with which the otherwise lengthy administration of such high doses can be avoided.
- the preparations according to the invention are usually administered in a dose of, for example, 50 to 150 U of prothrombin / kg of body weight, although the maximum doses can also be well above 150 U / kg of body weight (for example up to 300 or up to 500) without it being too thromboembolic side effects may occur.
- the present invention therefore also relates to dosage forms of the pharmaceutical preparations according to the invention which comprise a dose of at least 50 U prothrombin / kg body weight, preferably between 50 and 500 U / kg body weight.
- These dosage forms can be ampoules, syringes, or similar forms that can be applied directly or indirectly, and are already intended for direct administration.
- These include containers suitable for infusion, intramuscular or subcutaneous use or sets consisting of containers with the active ingredients as lyophilisate and a container with a pharmaceutically acceptable solution, suitable for reconstitution of the lyophilisate.
- the pharmaceutically acceptable solution or the pharmaceutical preparation contains salts, preservatives, buffers and the like.
- aqueous solutions examples include propylene glycol, polyethylene glycol, vegetable oils and injectable organic esters, such as ethyl oleate.
- Aqueous carriers are, for example, water, optionally mixed with alcohol, salt solutions (NaCl), Ringer's dextrose, etc. Antimicrobial substances, antioxidants, chelating agents or inert gases can be used as preservatives.
- the preparations according to the invention are also suitable for local treatment, application forms being selected which take effect at the site of a bleeding.
- These include solids or liquids, preferably in the form of a powder, plaster or wound dressing, ointments, suppositories, capsules, in particular gastric juice-resistant capsules, but also drops or sprays.
- the coagulation factors used can be both of plasma origin and proteins produced by recombinant DNA technology. It is essential in both cases that they are present in the pharmaceutical preparation in a purified form, in particular in a form freed from endogenous and exogenous phospholipids.
- a reconstitution solution is one pharmaceutically acceptable solution, which may contain ATIII or heparin. Due to the high degree of purity of the components of the preparations according to the invention, they can be reconstituted after a short solution time at room temperature, preferably less than 5 min, in particular less than 1 min, to form an optically clear solution with, for example, at least 10 U prothrombin / ml, even concentrations of up to 200 E prothrombin / ml solution can be achieved.
- An optically clear solution is defined by a maximum absorbance at 600 nm of 0.1 (for a solution with at least 5% by weight protein, with a layer thickness of 1 cm), based on the pure (buffer) solution as a reference .
- a solution with less than 70 Light Scattering Units (LSU), determined by measurement in a nephelometer at 340 nm and a layer thickness of 1 cm, is also considered to be clear.
- LSU Light Scattering Units
- the preparations according to the invention are extremely stable, ie they can be left to stand for a longer period of time before administration.
- FEIBA ® should not be left in the ready-to-administer state for longer than 1 hour, whereas the preparations according to the invention as a ready-to-use solution do not show any clotting activation or thrombogenicity at room temperature for a period of 3 hours or longer, which is why the preparations according to the invention can also be provided as an infusion solution, which can also be administered over a period of several hours.
- the pharmaceutical preparations are prescribed in suitable application devices, preferably as lyophilisate in Syringes that allow in situ reconstitution with a pharmaceutically acceptable solution.
- suitable application devices preferably as lyophilisate in Syringes that allow in situ reconstitution with a pharmaceutically acceptable solution.
- an application device is recommended, as shown in FIG. 1, in which the lyophilisates of, for example, prothrombin and factor Xa are preferably stored separately and can be administered if necessary after in situ reconstitution by means of a double-chamber syringe.
- prothrombin in a simple syringe, preferably in lyophilized form, optionally with a pharmaceutically acceptable solution for reconstitution (see FIG. 2).
- the prothrombin preparation can also be made available as a liquid preparation or in liquid deep-frozen form.
- the pharmaceutical preparations according to the present invention can be subjected to one or more virus inactivation treatments or treatments for virus depletion, for example chemical or chemical-physical treatment, heat treatment. and / or detergent treatment according to EP 0 159 311, EP 0 519 901 or EP 0 674 531 or a physical treatment such as that of nanofiltration.
- the preparations according to the invention enable safe and simple treatment of blood coagulation disorders, in which an effective onset of action can be observed within a very short time.
- the long half-life of the preparations according to the invention and their freedom from thrombogenic side effects or the absence of an anaphylactic reaction, which leads to an increase in the inhibitor titre, make it possible to treat the patient with blood coagulation disorders considerably better than known methods.
- the patient Due to the high concentration or dose of the preparation according to the invention, the patient can receive an active ingredient depot, which reduces the need for frequent treatments. The patient can therefore remain without treatment for a longer period of several days and, if necessary, treat himself as an outpatient by self-injection, possibly subcutaneously.
- the present invention furthermore relates to a process for the production of a purified pharmaceutical prothrombin preparation, which is characterized in that a prothrombin complex concentrate is subjected to chromatographic purification and the fraction containing prothrombin is processed to a pharmaceutical preparation.
- a prothrombin preparation is made available which fully meets the purity requirements for the pharmaceutical preparations according to the invention, in particular with regard to the freedom from side effects determined by the Wessler test.
- the method according to the invention is characterized by the combination of the following steps:
- Virus inactivation treatment preferably by heat treatment, in particular in the solid state, optionally dissolving the prothrombin complex preparation, a prothrombin-containing solution being obtained, optionally treating the prothrombin-containing solution with an alkaline earth metal salt as a solid carrier, wherein prothrombin is adsorbed and then desorbed, if appropriate concentrating once or several times, preferably by precipitation or ultra / diafiltration, and gel filtering the prothrombin-containing solution, treating the prothrombin-containing solution with an anion exchanger, prothrombin is adsorbed and then selectively desorbed,
- anion exchanger in principle all come anion exchanger in question, which have an affinity for prothrombin, such as DEAE Sephacel ®, DEAE-Sephadex ®, DEAE-Sepharose CL6B ®, DEAE-Sepharose Fast Flow ®, QAE-Sephadex ®, Q Sepharose Fast flow ®, Q Sepharose high performance ®, Q Sepharose Big Beads ® (all Fa 'Pharmacia.), DEAE-Tris-acryl ®, DEAE Spherodex® ®, Q-Hyper-D ® (all company Sepracor.);
- Macroprep DEAE ® Macroprep Q ® (all from BioRad); DEAE-Toyopearl ® , QAE-Toyopearl ® , Toyopearl Super-Q ® (all from Tosohaas),
- Fractogel EMD-TMAE ® Fractogel EMD-DEAE ®
- Fractogel EMD-DMAE ® Licrospher 1000 TMAE ®
- Licrospher 1000 DEAE ® Licrospher 4000 DMAE ® (all from MERCK).
- Phenyl-Sepharose High Performance ® (from Pharmacia) is preferably used as the gel for hydrophobic interaction chromatography, but also other chromatographic gels such as, for example, Butyl-Sepharose ® , Octyl-Sepharose ® , Phenyl-Sepharose ® , Phenyl-Sepharose Fast Flow High Sub ® , Phenyl-Sepharose Fast Flow Low Sub ® (all from Pharmacia),
- Macroprep-Methyl-HIC-Support ® Macroprep t-Butyl-HIC-Support ® (all from BioRad); TSK-Gel Butyl Toyopearl ® , TSK-Gel Phenyl Toyopearl ® and TSK-Gel Ether Toyopearl ® (all from Tosohaas).
- FIG. 3 A possible embodiment of the method according to the invention is shown in FIG. 3.
- the prothrombin preparation which can be produced with the method according to the invention, is not only characterized by an extremely high purity, which is close to the theoretically possible purity of 10 U / mg, but also by the fact that it is even at a dose of at least 150 E prothrombin / kg free of thromboembolic side effects, expressed by a score in the Wessler thrombosis model of at most 3 points, preferably at most 2 points, in particular less than 2 points, and moreover as a lyophilisate with a dissolution time of at most 1 min to a clear solution an activity of at least 10 U prothrombin / ml up to 200 U prothrombin / ml can be reconstituted.
- the biological activity of the prothrombin preparation is understood as the enzymatic activity which is obtained after activation of the prothrombin.
- the present invention relates to the use of purified prothrombinase factors, in particular purified prothrombin and optionally purified factor Xa for the manufacture of a pharmaceutical preparation for establishing supranormal concentrations of prothrombin in the blood of a patient or for establishing normal pro- thrombin concentrations in the blood in states with a reduced prothrombin level.
- the supranormal concentrations of prothrombin in the blood by administration of purified prothrombin and optionally purified factor Xa or other prothrombinase factors are at least 150%, preferably even at least 200%, corresponding to an activity of at least 1.5 U prothrombin / ml blood, preferably at least 2.0 up to 10 U / ml.
- the invention also relates to the use of purified prothrombinase factors, in particular purified prothrombin and optionally purified factor Xa, for the production of a pharmaceutical preparation for the treatment of factor VIII inhibitor states, haemophilia A or B and of Willebrand disease. It has been shown that a rapid, efficient and side effect-free treatment is possible in animal models for all these indications with the preparations according to the invention.
- the preparations according to the invention are preferably made available in a solution with a physiological pH, which preferably does not contain any free calcium ions.
- a physiological pH which preferably does not contain any free calcium ions.
- an acid buffer in the range of pH 4.5-6.5, preferably 5-6, which is removed, for example, from the factor Xa activity optimum and with which the activation of prothrombin is delayed and thus the stability of the Combination preparation can be increased again.
- all pharmaceutical additives and solutions suitable for factor II, V, Va, X and Xa can be used for the preparation of the preparations according to the invention ready for administration.
- the preparations according to the invention can also be used in non-hemophilic patients.
- Non-haemophilic patients also include those who have blood clotting disorders due to inhibitors of blood factors that are not factor VIII or factor IX.
- patients can be treated which show a disturbed thrombin generation caused by the absence or functional defect of one or more factors of extrinsic or intrinsic coagulation or the formation of antibodies against one or more of these factors or by the lack of the cellular receptor for one or more of these factors .
- a preparation according to the invention there may be an anticoagulant effect in vivo, making treatment, namely prophylactic or therapeutic administration, possible.
- the present invention thus relates to the use of at least 2 coagulation factors which are constituents of a prothrombinase or pro-prothrombinase, or the use of the preparation according to the invention, for producing a pharmaceutical preparation for the treatment of acute bleeding, an increased bleeding tendency or an increased risk of bleeding in non-haemophilic patients.
- thrombocytopaenia conditions due to impaired aggregation behavior of platelets or thrombopathies, e.g. Storage pool defects, or due to deficiency or dysfunction of platelet-associated proteins, but also bleeding conditions due to platelet deficiency (thrombocytopaenia).
- a side effect of anticoagulant therapy lies in the heparin-induced thrombocytopenia, which is also an indication for the preparation according to the invention.
- the present invention therefore relates to the use of at least 2 coagulation factors which are constituents of a prothrombinase or pro-prothrombinase for the production of a pharmaceutical preparation for the treatment of bleeding due to thrombocytopenia, in particular for the treatment of heparin-induced thrombocytopania.
- the pharmaceutical preparation produced according to the use according to the invention may have a primary hemostatic activity. points.
- the pharmaceutical preparation produced can be enhanced by the combination with proteins with primary hemostatic activity.
- a von Willebrand factor protein or a fraction of the von Willebrand factor with a defined collagen binding activity is particularly suitable for this.
- Another indication for the treatment of patients with bleeding disorders is the prevention or treatment of bleeding that occurs in connection with von Willebrand's Disease.
- This disease with and without the prevalence of coagulation factor inhibitors, entails an increased tendency to bleed or a risk of bleeding and in many cases leads to bleeding that is difficult to control.
- With the help of the preparation according to the invention it is possible to quickly stop such bleeding.
- a set for the treatment of patients with blood coagulation disorders, which comprises the following components: a) a pharmaceutical preparation containing at least 2 coagulation factors which are components of a prothrombinase or pro-prothrombinase and are free of phospholipids, and b) a Protein with primary hemostatic activity, especially vWF.
- Bleeding that is difficult to control can occasionally occur as a side effect of therapy with synthetic, semi-synthetic and biological coagulation inhibitors or anticoagulants or platelet function inhibitors. These substances intervene directly or indirectly in the coagulation system and can undesirably disrupt the natural coagulation process. There is therefore a need for antagonists for these substances.
- the use is of a prothrombin binkomplexes or a FEIBA ® -preparation for treatment of bleeding caused by anticoagulant therapy is known. See Irani MS et al. , The American Journal of Cardiology, Vol. 75, Feb. 15, 1995, p 422; Fareed J et al. , Haemostasis 1991, vol. 21 (suppl. 1) p 64-72; and Fareed J et al. , Seminars in Thrombosis and Hemostasis 1991, Vol. 17, No. 2, p 137.
- the coagulation factors mentioned are used for the production of a pharmaceutical preparation according to the invention for the treatment of bleeding as part of an anticoagulant therapy, in particular for the production of a pharmaceutical preparation as an antidote for a coagulation inhibitor or for an anticoagulant or for a platelet function inhibitor. It is essential that a risk of thrombosis associated with the presence of phospholipids is avoided. There is an increased risk of thrombosis, especially in patients treated with anticoagulants. According to the invention, however, the use of the phospholipids can be dispensed with, which surprisingly makes the antidote effect even more specific.
- a substance is preferably antagonized which is selected from the group consisting of APAP ((2S) -2- [4- [[(3S) -l-acetimidyl-3-pyrrolidinyl] oxy] phenyl] -3- ( 7- amidino-2-naphthyl) -propionic acid hydrochloride pentahydrate), benzamidine derivative, hirudin, heparin, heparin analogs, in particular pentasaccharides, AT III-heparin complex, AT III, antistasin, "tick anticoagulant peptides", inactive coagulation factors, in particular "active site "inhibited coagulation factors, TFPI, competitive ligands for platelet membrane surface receptors, in particular antibodies against GP Ilb
- Antagonization of a platelet function inhibitor is particularly indicated in the case of ticlopidine or acetylsalicylic acid.
- Acute bleeding is particularly critical in the area of the brain. Therefore, there is a need to prevent or treat intracranial bleeding, such as intraventricular hemorrhage (IVH).
- IVH intraventricular hemorrhage
- the preparation according to the invention is also particularly suitable for this indication, the improved treatment of premature babies being made possible above all.
- the corresponding sets are provided which contain the pharmaceutical preparation according to the invention as a component. Furthermore, substances that enhance the hemostatic effect, e.g. a protein with primary hemostatic activity, especially vWF may be included.
- a set for anticoagulant therapy naturally contains the corresponding anticoagulant and the pharmaceutical preparation according to the invention as an antidote.
- FIG. 5 shows the spectroscopic analysis of an example of the preparations (A) according to the invention in comparison to standard preparations [activated prothrombin complex (B), prothrombin complex (C)];
- a lyophilized prothrombin complex factor preparation which contained factors II, IX, X as well as protein C and protein S, was carried out according to the method of Brummelhuis, HGJ, Preparation of the Prothrombin Complex.
- a third wash was carried out in an analogous manner with 20 mM Tris-HCl buffer, pH 7.0, containing 150 mM NaCl.
- the prothrombin complex fraction was eluted with 1 M sodium phosphate solution, pH 7.0, 25 ml of this solution per g of calcium phosphate being stirred at room temperature for 1 hour and then the remaining precipitate being separated off by centrifugation as above.
- the supernatant was then subjected to ammonium sulfate precipitation with 366 g of ammonium sulfate per 1 h at 4 ° C. with stirring.
- the precipitate containing the prothrombin complex fraction was centrifuged off as above.
- the precipitate was in a 25 mM trisodium citrate dihydrate buffer containing 100 mM NaCl, 1 mM benzamidine hydrochloride, pH 6.0, was added and ⁇ on a column filled with Sephadex ® G-25, at 4 ° C with a linear flow rate of 1 cm / min against 25 mM trisodium citrate buffer containing 100 mM NaCl and 1 mM benzamidine hydrochloride, pH 6.0, buffered to separate the ammonium sulfate.
- the UV absorption at 280 nm and the electrical conductivity were measured in the eluate stream.
- the protein-containing fractions were combined and then subjected to ion exchange chromatography on DEAE-Sepharose FF ® , from Pharmacia.
- the chromatography was carried out at 22 ° C. Before the proteins were applied, the column had been equilibrated with a 25 mM trisodium citrate dihydrate buffer containing 100 mM NaCl, 1 mM benzamidine hydrochloride, pH 6.0.
- the protein fractions were eluted in several stages with a buffer 1 (25 mM trisodium citrate dihydrate, 1 mM benzamidine hydrochloride, 245 mM NaCl, pH 6.0), buffer 2 (25 mM trisodium citrate dihydrate, 1 mM benzamidine hydrochloride, 270 mM NaCl, pH 6.0) ) and a buffer 3 (25 mM trisodium citrate dihydrate, 1 mM benzamidine hydrochloride, 400 mM NaCl, pH 6.0). Elution with buffer 1 was carried out with 2.4 column volumes, inert protein being separated off in the process.
- buffer 1 25 mM trisodium citrate dihydrate, 1 mM benzamidine hydrochloride, 245 mM NaCl, pH 6.0
- buffer 2 25 mM trisodium citrate dihydrate, 1 mM benzamidine hydrochloride, 270 mM NaCl, pH 6.0
- the elution was carried out with 5.6 column volumes with buffer 2, fractions being collected here, which were analyzed for the content of factor II, factor X, protein C and factor IX.
- the factor X containing fractions free of factor II, IX and protein C were pooled.
- Factor II was desorbed by elution with buffer 3 (1.9 column volume), fractions being collected again and the content of factor X, factor IX and factor II being examined.
- the fractions containing factor II were pooled. Both factor II and the pool containing factor X could optionally be subjected to additional treatment for inactivating pathogenic contaminants by adding 1 M KSCN and incubating at 22 ° C. for several hours.
- a buffer 25 mM Tris-HCl, 3 M NaCl, pH 7 , 4
- Factor II was eluted from the column by gradient elution with 11.5 column volumes of 3 M - 0.9 M NaCl with simultaneous collection of fractions, pooling those fractions which contained factor II activity but were free from factor X and factor IX were.
- the collected Factor II fractions were then concentrated ten times by ultra / diafiltration over an ultrafiltration membrane with a cut-off of 30 kD and against a buffer containing 4 g of trisodium citrate dihydrate / 1.8 g NaCl / 1, pH 7.0. buffered.
- a factor II preparation prepared in this way had a specific activity of 6.9 U / mg protein.
- the factor II activity was determined using the 1-step method, based on the thromboplastin time, using a factor II deficient plasma against the international factor II standard using the reagent combination from IMMUNO, Vienna.
- Other coagulation factors were traces or no longer detectable in coagulation analyzes (factor VII ⁇ 0.00002 E / E factor II, factor IX 0.0002 E / E factor II, factor X 0.004 E / E factor II, protein C 0.003 E / E factor II and factor VIII ⁇ 0.0002 E / E factor II).
- factor II As an alternative production method for a highly purified factor II, a method was also used in which factor IX was first separated from a lyophilized prothrombin complex factor preparation (see Example 1) by means of hydrophobic chromatography, then factor II was isolated and then factor II Chromatography on hydroxylapatite was highly purified.
- the prothrombin complex factor preparation was as in Example 1.
- factor II desorbed from the column.
- the fractions containing factor II were collected and concentrated via ultra / diafiltration over polysulfone membranes with a cut-off of 30 kD until the factor II concentration was 50-100 U / ml.
- a factor II preparation prepared in this way had a specific activity of at least 7 U / mg protein.
- Other coagulation factors, in particular factor IX and factor VIII, were only detectable in traces or not at all, as in the preparation from example 2.
- a pharmaceutically acceptable buffer eg 4 g trisodium citrate dihydrate / 1.8 g NaCl / 1, pH 7.0.
- the factor X fraction prepared as described in example 1 was then further processed into factor Xab as described in DE 43 25 872, the highly purified factor Xa preparation obtained in this way being lyophilized in the presence of 1 g / 100 ml of human albumin. Such a preparation was free from other coagulation factors; the factor Xa contained a specific activity of 120 U / mg protein before addition to the albumin.
- Example 3 The preparation, described in Example 3, containing highly purified factor II was freeze-dried without the addition of stabilizers, more than 80% of the initial activity being retained after lyophilization.
- a factor II preparation prepared according to Example 3 was filled into a 50 ml vial at a concentration of 100 U / ml to 20 ml and snap-frozen at -80 ° C.
- a solution of a highly purified factor Xa which had been prepared in accordance with DE 43 25 852 and had a concentration of 500 U / ml, was then metered into the frozen factor II solution in an amount of 30 ⁇ l. The freezing of the small volume immediately prevented a mixture of factor II and factor Xa phase. It was then freeze-dried.
- the lyophilisate was diluted with 20 ml A.dest. reconstituted, mixed and immediately prepared for administration.
- Antithrombin III and / or Antithrombin III heparin complex
- a double double-chamber syringe body as described in AT 382 783.
- these would otherwise have to be reconstituted and mixed together in a defined ratio before they can be administered to the patient.
- the filling of the corresponding lyophilisates in a double-chamber syringe system enables an exact dosage to a predeterminable activity of the preparation for the treatment of inhibitor hemophilia, e.g. on conventional FEIBA units that can be determined in accordance with AT 350 726.
- the effective mixture is made in situ upon injection.
- the two double-chamber syringe bodies each contain lyophilisates of the active ingredients, Factor II and Factor Xa, which, by adding the solvent, A.dest., Dissolve immediately due to the easy solubility of the highly purified proteins and immediately after pressing the syringe plunger Mix in the mixing head to be infused into the patient (see Fig. 1).
- factor II Due to the high stability of factor II in solution, this is also suitable as a solvent for factor Xa in the dosage form of a double-chamber syringe.
- a solution of highly purified factor II, for example prepared according to example 2 in a physiologically tolerable citrate buffer (4 g trisodium citrate dihydrate / 1.8 g NaCl / 1, pH 7.0) in a concentration of 100 U factor II / ml is used Antithrombin III, Immuno Wien, added (1 U Antithrombin III / E factor II).
- a double-chamber syringe see Fig. 2
- this solution is used as a solvent for the freeze-dried powder of a highly purified factor Xa.
- Factor II was purified as described in Example 2 and as a solution in a concentration of 60 U / ml in a buffer containing 4 g / 1 trisodium citrate dihydrate, 8 g / 1 NaCl, pH 7.0, at 5 ° C, at 22 ° C, stored at 37 ° C and at 50 ° C. At storage temperatures of 5 ° C and 22 ° C, samples were taken every 24 h, for storage at 37 ° C and at 50 ° C, the samples were taken over 24 h at the time 1 h, 2 h, 4 h, 8 h and 24 hours. Factor II activity was determined in each of the samples.
- the analysis approach consisted of 250 ul Thrombotest ® (Nycomed Pharma AS, Oslo, Norway), a preparation containing thrombo plastin from bovine brain and adsorbed bovine plasma which has been preincubated for 3 min at 37 ° C. 50 ⁇ l of a sample were then added and the clotting time was determined using a spherical coagulometer (KC4, Amelung). Bovine thromboplastins are particularly sensitive to activated coagulation factors. Correspond-
- a high titer factor VIII inhibitor plasma (55 BU / ml) was pre-cooled in an ice bath and with PTT reagent (IMMUNO, Vienna) and the sample to be tested, both also pre-cooled in an ice bath, in a ratio of 1 + 1 + 1 at 37 ° C incubated for 1 min. Then 1 part of a 0.05 M CaCl 2 solution was added and the clotting time of the test mixture was determined using a spherical coagulometer from Amelung, model KC-4. The preparations to be tested were further diluted 1:10 in a buffer containing 7 g NaCl / 1 and 6 g trisodium citrate dihydrate / !, and with this concentration tration used in the test. Under these conditions, highly purified factor II, alone and in combination with highly purified factor Xa, in combination with antithrombin III and heparin were tested. The clotting times are shown in the table below.
- the clotting time of the test mixture was determined using pure sodium chloride trisodium citrate buffer. This was 148 seconds. It was only possible to significantly reduce the clotting time of the inhibitor plasma by adding factor II / Xa with or without antithrombin III or heparin.
- FEIBA STIM 4, Immuno which is the conventional preparation for the treatment of factor VHI inhibitor patients, in different concentrations in the same test batch, it was possible to determine that the FEIB activity of the preparation contained 10 U / ml factor II and 0.1 U factor Xa / ml, corresponds to approx. 25 U FEIBA / ml.
- a factor VIII inhibitor hemophilia rabbit model was used to test the in vivo activity of the preparation according to the invention. Approximately White New Zealand rabbits weighing 2 kg were anesthetized. After anesthesia had occurred, the right femoral vein was prepared and permanent venous access was created. Through this 0.5 ml / kg body weight of a human factor VIII inhibitor plasma (1500 BU / ml) was infused over 10 min. 30 minutes after the completion of the infusion, the bleeding characteristic was checked using a modified method Giles et al. , Blood 60: 727-730 (1982). For this purpose, the fur was shaved around a claw of the rabbit's rear paw in order to prevent blood which escapes during the later bleeding from being absorbed by the fur.
- the cuticles were injured using claw pliers; immediately thereafter, filters were established underneath so that the blood could drip directly onto the filter without being soaked up by capillary action to prevent a blood clot from being destroyed.
- the filter units were changed every 2 min, the exiting blood was collected in fractions. Blood collection continued for 30 minutes, after which the wound was closed if the bleeding had not stopped.
- the filters were extracted with 0.04% ammonium hydroxide solution over 5 h, during which the erythrocytes, which were collected with the blood in the filter, lysed.
- the hemoglobin was extracted by a 10-minute ultrasound treatment and determined quantitatively, photometrically at 416 nm against a calibration curve.
- the bleeding characteristic of the nail cut was determined by plotting the amount of blood per 2 minute fraction against time.
- the accumulated blood loss was determined by plotting the volume of the individual blood fractions against time.
- the gradient of the cumulative bleeding between 10 and 20 min was used as the criterion relevant for the bleeding. This value was independent of the initial amount of blood, which fluctuated from rabbit to rabbit depending on the claw cut.
- the increase in the bleeding characteristics in 10 to 20 min observation intervals served as a measure of the intensity of the bleeding.
- a slope equal to zero meant that the bleeding had stopped, a slope> 0 with a correlation coefficient of> 0.8 meant that there was constant bleeding.
- Healthy rabbits had a bleeding intensity of ⁇ 2 ⁇ l blood / min under the test conditions.
- Factor VIII inhibitor rabbits showed a bleeding intensity of approximately 50 ⁇ l blood / min (see FIG. 6).
- a von Willebrand factor / factor VHI inhibitor model was established by rabbits using goat anti-von Willebrand factor / factor VIII antiplasm, which is obtained by immunizing goats with a purified factor VIII / von Willebrand factor - Preparation was obtained, infused at a dose of 1 ml / kg body weight. Animals pretreated in this way showed an increased tendency to bleed (see FIG. 7). The bleeding characteristics were measured by claw cuts in these animals at the same time as the test substance was infused and 30 minutes after the test substance had been infused.
- factor II By administering factor II as a bolus of 2.5 ml in a dosage of 75 U / kg, the initially increased bleeding intensity from 77 ⁇ l / min to 31 ⁇ l / min (1st claw cut) or 12 ⁇ l / min (2nd claw cut ) can be reduced.
- factor II 75 U / kg
- factor Xab prepared according to Example 4
- the bleeding tendency could be increased from the initial value to 18 ⁇ l / min with the 1st claw cut and 5 ⁇ l / min with the 2nd claw cut. This normalized the abnormally increased bleeding behavior of the inhibitor animals to the level of the healthy control animals (4 ⁇ l / min).
- Rabbits were put under pentobarbital anesthesia, the jugular vein of the animals was dissected and provided with loose ligatures at a distance of 1-2 cm.
- the substances to be tested were injected into the ear vein opposite the freely prepared jugular vein. The injection took place within 15 seconds. After a waiting time of 10-15 seconds, the vein piece was disconnected. After a further 10 min, the pinched-off vein piece was removed and cut open in a citrate buffer in a petri dish and the thrombi obtained were evaluated using a scale between 0 and 4 (see table).
- the substances were examined in six animals each, which received 75 U factor II / kg, 0.55 U factor Xa / kg and 75 mE antithrombin HI / kg either alone or in combination.
- the following table shows the mean value of the Wessler score of six animals examined. Pure citrate buffer, which was also used as a dilution buffer, was used as a control.
- a preparation containing factor II and factor Xa according to example 6 was tested for its effectiveness in 6 rabbits each with induced factor VIII inhibitor hemophilia (see example 14). The dose tested was as described in Example 15. The animals were infused with pure buffer as a control.
- test substances were infused over 30 min, corresponding to approximately 15 min / kg body weight, using an automatic infusion pump at an infusion rate of 1 ml / min.
- second experiment the same dose was given to the animals as a bolus within 30 seconds in a small injection volume of 2.5 ml / kg body weight.
- the bleeding intensity was now measured during and after substance administration. It was shown that both with slow infusion with a large infusion volume and with the rapid injection of a small volume dose, but with identical doses related to the body '
- the bleeding time is then determined using Simplate R disposable catches (Organon, Technica). At a distance of approx. 1.5 cm from the base of the tail, a longitudinal section is made dorsally and then ventrally and the bleeding time is measured. The mean value from the two individual measurements is the bleeding time.
- the test substance is then applied (buffer, factor II according to example 2, factor Xa according to example 4 and partial prothrombinase according to example 6); The bleeding time is determined again 30 minutes later. Healthy Sprague-Dawley rats (Charles River) are used for control.
- the study is carried out in groups of 10 animals, the complex of partial prothrombinase in 2 doses, 75 U / kg body weight (KG) prothrombin and 0.55 U / kg KG factor Xa and 150 U / kg KG prothrombin and 1.1 E / kg body weight factor Xa.
- the individual components and buffers are given as a control.
- the mean bleeding times measured in the individual test groups are given in the table below. Healthy rats have a bleeding time of 168 + 5 seconds under the same experimental conditions, while rats with thrombopathy have an extended bleeding time of 335 ⁇ 10 seconds. By administering the partial prothrombinase, this abnormally increased bleeding time can be reduced to approx. 270 seconds.
- the data are given as mean values ⁇ standard deviation.
- the group means were compared using the Student T-Test.
- n.b. not determined ns difference to control group (0 U / kg FII and 0 U / kg FXa) not significant * difference to control group (0 U / kg FII and 0 U / kg FXa) significant with p ⁇ 95% *** difference to control group (0 U / kg FII and 0 U / kg FXa) significant with p ⁇ 99.9%
- a dog with congenital von Willebrand factor deficiency with an immeasurable von Willebrand factor activity and antigen plasma level and a 50% reduced factor VIII plasma concentration is treated with a partial prothrombinase in a dose of 100 U / kg body weight.
- the dog is anesthetized and then the partial prothrombinase prepared according to Example 6 is administered intravenously as a bolus.
- the test substance Immediately before administration of the test substance and 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 24 hours and 48 hours after infusion, blood samples are taken, this plasma is produced and the prothrombin, thrombin and factor VIII concentration in the plasma samples certainly .
- the cutaneous bleeding characteristics are determined before the partial prothrombinase is administered and 3 and 24 h after the injection.
- the fur around the claw is shaved to prevent blood from escaping from the fur from the later bleeding.
- the cuticles are injured using claw pliers.
- filters Pierman P5000 protective filter, Gilson
- a partial prothrombinase in a composition of 57 U factor II and 1.2 U factor Xa was dissolved in 20 mM Tris-HCl buffer containing 150 mM NaCl, pH 7.4 and incubated for 15 min at room temperature to form the complex. / An aliquot of 50 ⁇ l was then removed and incubated with 50 ⁇ l of a tris-imidazole buffer, pH 8.4, at 37 ° C. for 90 seconds.
- factor Xa was used in the same concentration but without prothrombin in this test and a conversion rate of the chromogenic substrate of 0.064 ⁇ OD / min was found.
- Recombinant hirudin (Rhein-Biotech) was added to the partial prothrombinase in a concentration of 0.0025 U / ml and the conversion rate of the chromogenic substrate was also examined. It was found that after subtracting the substrate conversion of the pure factor Xa (0.064 ⁇ OD / min), no further substrate conversion could be measured, which was due to a complete neutralization of the hirudin.
- hirudin In addition to the effective and specific thrombin inhibitor, hirudin, the selective factor Xa inhibitor, recombinant tick anticoagulant peptide, a recombinant equivalent of the serine protease inhibitor from Ornithodoros moubata, whose anticoagulant in vivo activity of GP Vlasuk, D.Ramjit, T. Fujita et al. in Comparison of the In Vivo Anticoagulant Properties of Standard Heparin and the Highly Selective Factor Xa Inhibitors Antistasin and Tick Anticoagulant Peptide (TAP) in a Rabbit Model of Venous Thrombosis.
- TRIP Antistasin and Tick Anticoagulant Peptide
- Thrombos Haemostas 1991; 65: 25W-262 was added in a concentration of 50 ⁇ g / ml. Already 30 minutes after the addition of the recombinant tick anticoagulant peptide, no enzyme activity could be measured with the chromogenic substrate. The experiment shows that partial prothrombinase is an efficient antagonist of the peptide anticoagulants, hirudin and tick anticoagulant peptides.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU92453/98A AU9245398A (en) | 1997-09-19 | 1998-09-21 | Preparation for the therapy of disorders related to blood clotting |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT0159597A ATA159597A (de) | 1997-09-19 | 1997-09-19 | Präparat zur behandlung von blutgerinnungsstörungen |
ATA1595/97 | 1997-09-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999015197A1 true WO1999015197A1 (de) | 1999-04-01 |
Family
ID=3516826
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AT1998/000228 WO1999015197A1 (de) | 1997-09-19 | 1998-09-21 | Präparat zur behandlung von blutgerinnungsstörungen |
Country Status (3)
Country | Link |
---|---|
AT (1) | ATA159597A (de) |
AU (1) | AU9245398A (de) |
WO (1) | WO1999015197A1 (de) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT506216B1 (de) * | 2008-02-13 | 2009-07-15 | Peter Dr Hernuss | Zusammensetzung zur aufnahme über mukoses gewebe |
CN106916802A (zh) * | 2003-12-01 | 2017-07-04 | 诺和诺德医疗保健公司 | 液体因子vii组合物的病毒过滤 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5510248A (en) * | 1993-06-22 | 1996-04-23 | The University Of British Columbia | Stable recombinant meizothrombin-like polypeptides |
DE19531637A1 (de) * | 1995-08-28 | 1997-03-06 | Immuno Ag | Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung |
EP0776969A2 (de) * | 1995-11-24 | 1997-06-04 | IMMUNO Aktiengesellschaft | Verfahren zur Herstellung von Proteinen durch kontrollierte proteolytische spaltung von Pro-Proteinen |
EP0796623A2 (de) * | 1996-03-20 | 1997-09-24 | IMMUNO Aktiengesellschaft | Pharmazeutisches Präparat zur Behandlung von Blutgerinnungs-störungen |
WO1998044942A1 (de) * | 1997-04-08 | 1998-10-15 | Baxter Aktiengesellschaft | Immuntolerante prothrombinkomplex-präparation |
-
1997
- 1997-09-19 AT AT0159597A patent/ATA159597A/de not_active Application Discontinuation
-
1998
- 1998-09-21 WO PCT/AT1998/000228 patent/WO1999015197A1/de active Application Filing
- 1998-09-21 AU AU92453/98A patent/AU9245398A/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5510248A (en) * | 1993-06-22 | 1996-04-23 | The University Of British Columbia | Stable recombinant meizothrombin-like polypeptides |
DE19531637A1 (de) * | 1995-08-28 | 1997-03-06 | Immuno Ag | Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung |
EP0776969A2 (de) * | 1995-11-24 | 1997-06-04 | IMMUNO Aktiengesellschaft | Verfahren zur Herstellung von Proteinen durch kontrollierte proteolytische spaltung von Pro-Proteinen |
EP0796623A2 (de) * | 1996-03-20 | 1997-09-24 | IMMUNO Aktiengesellschaft | Pharmazeutisches Präparat zur Behandlung von Blutgerinnungs-störungen |
WO1998044942A1 (de) * | 1997-04-08 | 1998-10-15 | Baxter Aktiengesellschaft | Immuntolerante prothrombinkomplex-präparation |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106916802A (zh) * | 2003-12-01 | 2017-07-04 | 诺和诺德医疗保健公司 | 液体因子vii组合物的病毒过滤 |
AT506216B1 (de) * | 2008-02-13 | 2009-07-15 | Peter Dr Hernuss | Zusammensetzung zur aufnahme über mukoses gewebe |
Also Published As
Publication number | Publication date |
---|---|
AU9245398A (en) | 1999-04-12 |
ATA159597A (de) | 2000-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0796623B1 (de) | Pharmazeutisches Präparat zur Behandlung von Blutgerinnungsstörungen | |
DE4416166C2 (de) | Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen | |
DE60036017T2 (de) | Verfahren zur thrombolyse durch lokale behandlung mit reversibel inaktiviertem, angesäuertem plasmin | |
AU2008203028B2 (en) | Pharmaceutically stable hemostatic compositions | |
DE3617753C2 (de) | ||
DE19903693A1 (de) | Protease zur Aktivierung des Gerinnungsfaktors VII | |
DE69333931T2 (de) | Verwendung von Krillenzymen zur Behandlung von Zahnbelag | |
DE4411143C2 (de) | Thrombosemittel | |
AT405485B (de) | Eine das vwf-propeptid enthaltende pharmazeutische präparation | |
EP0041173A1 (de) | Die Blutkoagulation aktivierende Produkte und Verfahren zu deren Herstellung | |
AT409334B (de) | Pharmazeutisches präparat enthaltend vitamin k-abhängige einzelfaktoren | |
EP1528930B1 (de) | Thrombingenerierfähige und thrombinhaltige pharmazeutische wirkstoffzubereitungen und arzneimittel | |
DE4416180C2 (de) | Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen und Verfahren zur Herstellung dieses Präparats | |
WO1999015197A1 (de) | Präparat zur behandlung von blutgerinnungsstörungen | |
EP0255651B1 (de) | Mittel zur Therapie faktor VIII-resistenter Hämophilie A und Verfahren zu seiner Herstellung | |
AT408612B (de) | Verwendung von mindestens 2 gerinnungsfaktoren zur herstellung eines pharmazeutischen präparats | |
DE69833727T2 (de) | Verfahren zur Behandlung der Gefässerkrankungen mit aktiviertem Protein C | |
AT407116B (de) | Pharmazeutisches präparat zur behandlung von blutgerinnungsstörungen | |
AT404673B (de) | Pharmazeutisches präparat zur behandlung von blutgerinnungsstörungen | |
AT408947B (de) | Pharmazeutisches präparat zur behandlung von blutgerinnungsstörungen | |
WO2024012853A1 (de) | Arzneimittel zur förderung der hämostase | |
Seegers et al. | Wayne State University College of Medicine, Detroit | |
DE2316854A1 (de) | Fibrinolytisches material | |
WO1999009184A1 (de) | Plasminogenaktivator mit verbesserter zymogenität und verminderter fibrinbindung | |
WO1999009185A1 (de) | Plasminogenaktivator mit verbesserter zymogenität |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
ENP | Entry into the national phase |
Ref country code: AT Ref document number: 1998 9148 Date of ref document: 19990401 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 19989148 Country of ref document: AT |
|
122 | Ep: pct application non-entry in european phase |